Table. 2.

Comparison of pathologic findings and clinical outcomes based on detectable de novo DSA

Variable Undetectablede novo DSA (n=14) Detectablede novo DSA (n=21) P-value
Glomerulitis (g score >1) 6 (46.2) 15 (71.4) 0.168
Peritubular capillaritis (ptc score >1) 8 (57.1) 17 (81.0) 0.151
Microvascular inflammation (g+ptc score >1) 11 (78.6) 20 (95.2) 0.279
Arteritis (v score >0) 2 (14.3) 5 (23.8) 0.676
Tubulitis (t score ≥1) 11 (78.6) 16 (76.2) 1.000
Transplant glomerulopathy (cg score ≥1) 9 (69.2) 18 (85.7) 0.387
Arterial intimal fibrosis (cv score >1) 3 (21.4) 7 (33.3) 0.704
IF/TA (ci+ct scores) 1.000
2–3 6 (42.9) 10 (47.6)
≥4 8 (57.1) 11 (52.4)
Positive C4d 6 (42.9) 10 (47.6) 1.000
Allograft function
MDRD eGFR (mL/min/1.73 m2)
1 Month before diagnosis 43.8±10.5 45.7±13.5 0.654
At diagnosis 34.3±9.5 38.8±12.3 0.261
1 Month after diagnosis or treatment 33.6±10.6 44.1±18.4 0.043
3 Months after diagnosis or treatment 31.3±11.2 44.9±18.3 0.092
6 Months after diagnosis or treatment 29.3±10.6 39.9±16.4 0.033
12 Months after diagnosis or treatment 27.4±11.7 36.9±19.8 0.174
Proteinuria at diagnosis (g/day) 1.7 (0.4–5.4) 1.1 (0.3–2.2) 0.207
Proteinuria (≥1.5 g/day) at diagnosis 7 (50.0) 6 (28.6) 0.288
Rituximab+IVIG 3 (21.4) 10 (47.6) 0.162

Values are presented as number (%), mean±standard deviation, or median (range).

DSA, donor-specific antibody; IF/TA, interstitial fibrosis/tubular atrophy; MDRD, modification of diet in the renal disease; eGFR, estimated glomerular filtration rate; IVIG, intravenous immunoglobulin.

Korean J Transplant 2021;35:33~40 https://doi.org/10.4285/kjt.20.0052
© Korean Journal of Transplantation